Huma Qamar

Company: Ocugen, Inc

Job title: Chief Medical Officer

Seminars:

Clinical Insights From Ocugen’s OCU410 Gene Therapy for Dry AMD and Geographic Atrophy 9:00 am

Characterizing Vector and promoter selection – ensuring compatibility with target retinal layers and pathologic processes  Exploring strategies to minimize immunogenicity and dosing risk in elderly populations  Unpacking the latest updates from the ArMaDa Phase ½ trial, discussing early safety signals, trial design for GA populations and long-term potential for slowing disease progression Read more

day: Day1